A global biopharmaceutical research company committed to developing innovations for the treatment of the some most challenging diseases in the world and contributing to global health improvement through the development and manufacture of innovative medicines and leadership in the biopharmaceutical industry.
Today, our medicines help 57 million people in over 175 countries, and we have made significant progress in research and development of new products.
Science and innovation are the core of our business. We are focused on developing and bringing to the market innovative medicines in therapeutic areas in which we have deep expertise and have a significant impact. We support public priorities consistent with our mission to develop and implement innovative treatment methods, to provide patients with life-saving therapy that can change their lives for the better.
AbbVie’s scientific achievements are driving the improvement of healthcare standards through research and development in many areas of medicine, including oncology, immunology, virology, neurology and ophthalmology.
AbbVie’s portfolio of highly efficacious medicines with a favorable safety profile for the treatment of more than 60 diseases and conditions, including HIV / AIDS, hepatitis C, immune-mediated and oncological diseases, as well as drugs used in ophthalmology, aesthetic medicine, neonatology, neurology and anesthesiology.
We invest in innovative technologies and platforms, strive to innovate within our forward-looking pipeline, and offer new therapeutic solutions to improve the lives of our patients. AbbVie has 8 R&D centers and 20 manufacturing sites around the world.
AbbVie partners share our commitment to finding solutions to the most complex healthcare challenges. AbbVie collaborates with biotech companies, universities, non-profit and government organizations to continually advance science and develop innovative solutions for the patients.
In May 2020, AbbVie merged with Allergan. This is a transformational step that has helped expand and diversify AbbVie’s business while maintaining a focus on innovative science. These new opportunities will allow the company to continue investing in the medicine of the future, increase patient coverage in a wider range of therapeutic areas around the world, seek and find solutions for diseases which treatment options are still very limited.
AbbVie’s key therapeutic areas include immunology, oncology, virology and neurology, aesthetic medicine and eye care.
AbbVie strives to change patients’ lives by developing innovative therapies. For 20 years, we have been at the forefront of immunology, making scientific discoveries and delivering high quality manufacturing standards to ensure that patients receive the best medicines they need most on time. Based on our leadership in this area, we have moved forward with the development of new treatments that are in various stages of review or approval by government agencies around the world. In 2019, AbbVie launched a new generation drug that is changing the paradigm for treating three rheumatic diseases in adults: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and moderate to severe atopic dermatitis in adults and children over 12 years of age. AbbVie has been cooperating with the Association of Rheumatologists of Russia for over 12 years, and during this time several large-scale projects have been implemented with the aim of expanding educational opportunities for healthcare professionals and patient access to modern therapy options.
Our goal is to change the paradigm of cancer treatment. Our goal is to change the paradigm of cancer treatment. We have several approved products, and we continue to focus on achieving better, long-term control of oncohematological diseases, including therapy for chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, acute myeloid leukemia and multiple myeloma. We are also investing in advanced technologies and working together with leading experts in this area to create promising approaches to the treatment of solid tumors. Today targeted therapy for chronic lymphocytic leukemia and acute myeloid leukemia is available in Russia.
AbbVie is committed to make a significant contribution to efforts aimed at achieving the World Health Organization’s goal of eliminating chronic hepatitis C (HCV) by 2030. We have developed innovative therapy options that allow more people to be cured in a shorter time, because each patient cured increases the possibility of eliminating this disease. We are also constantly working to accelerate the path to HCV elimination by developing partnerships with the hepatitis C community, improving standards of care to improve patient access to diagnosis and treatment, and simplifying treatment by reducing the patient’s path to recovery.
Our commitment to help people with neurodegenerative diseases remains unchanged. Every challenge in this uncharted territory makes us more determined and makes us harder to find and propose solutions for patients, people helping patients, and doctors. AbbVie’s neurological portfolio consists of approved medicines that are used to treatadvanced phases of Parkinson’s disease, and promising developments for the treatment of other neurodegenerative diseases, including Alzheimer’s, Parkinson’s and multiple sclerosis.
Allergan aesthetics portfolio is well known throughout the world. Allergan continues to research new treatment options and devices that safely and effectively help in treatment of skin conditions, reduce fat, and maintain clear lines and volume of the face. As part of AbbVie, Allergan Aesthetics will continue to implement its customer service programs and develop and expand its leadership position.
As part of AbbVie, Allergan’s mission to protect and improve the quality of life of the millions of people who annually experience vision loss remains unchanged. Allergan products are the best in the industry for the treatment of glaucoma, ocular hypertension and other conditions. Scientists are currently engaged in promising areas of research for the treatment of retinal diseases such as macular edema, diabetic macular edema, and age-related macular degeneration.
AbbVie is constantly working to improve the availability of innovative products for patients. Our key products in Russia are localized in partnership with leading Russian pharmaceutical manufacturers. As a socially responsible company, AbbVie supports educational programs for healthcare professionals, patients and the general public in Russia, both in clinical practice and in order to raise public awareness of socially significant diseases.
AbbVie has been operating in Russia for over 40 years, until 2013 as part of Abbott. AbbVie products registered in Russia help with more than 40 diseases and conditions. The company’s activities and plans correspond to the key priorities of the state policy of the Russian Federation in the field of healthcare, in such areas as increasing life expectancy, combating cancer, improving health and improving the quality of life of the population, prevention and treatment of socially significant diseases.
The use of innovative medicines allows to achieve significant advantages in the treatment of patients, improves clinical and economic indicators. 15 AbbVie products are on the VED and ONLS lists and 11 medicines are localized.
We are collaborating with a number of health authorities and organizations around the world to conduct clinical research on the COVID-19 coronavirus. AbbVie supports clinical and basic research by working closely with European health authorities, as well as the U.S. Food and Drug Administration, the U.S. Centers for Disease Control and Prevention, the National Institutes of Health and the U.S. Office of Advanced Biomedical Research and Development to coordinate their actions in this direction.
AbbVie has donated $ 35 million to support healthcare systems and communities struggling with the COVID-19 pandemic. AbbVie will set aside up to US $ 5 million of the total $ 35 million in COVID-19 pandemic funding through AbbVie AbbVie COVID-19 Community Resilience Fund. The foundation will provide financial support in the amount of up to $ 1 million to organizations working to help communities in regions with insufficient resources exposed to COVID-19.
In addition, AbbVie is doubling down on donations of its employees aimed at combating COVID-19. Instead of the usual one-to-one ratio, the AbbVie Foundation introduces a two-to-one ratio, and will allocate $ 2 for every $ 1 donated by an employee of the company.
From 2014 to 2019, AbbVie Russia was included in the list of the best employers in Russia according to the results of a study conducted by AXES Management in cooperation with Aon Hewitt and Kincentric, world leaders in the field of HR consulting. In 2021 Great Place to Work® and PEOPLE magazine have honored AbbVie as one of the 2021 PEOPLE Companies that Care®. This is AbbVie’s third consecutive time being named to this list.
The number of employees in Russia is 379 people.
125196, Moscow, Lesnaya str. 7
Tel.: +7 495 258 42 77
Fax: +7 495 258 42 87
E-mail: russia.info@abbvie.com
